



One Wales Medicines Process work programme August 2023

NB. In order of One Wales Medicines Assessment Group assessment/review date, most recent first.

*Welsh Government will ratify all new OWMAG decisions made from 01/01/2023 onwards

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Abiraterone	Treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer.	26/09/2022	04/11/2022	N/A	Supported	13/11/2023	
Adalimumab	Treatment of paediatric patients with severe refractory non-infectious uveitis	22/08/2016	11/10/2016	N/A	Supported - partially superseded by AWMSG advice 08/12/2017	13/11/2023	
Vonicog alfa	On-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with severe von Willebrand disease	26/09/2022	04/11/2022	N/A	Supported	13/11/2023	

**One Wales work programme
August 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Dostarlimab	First line treatment of locally advanced stage II/III deficient mismatch repair (dMMR) / high microsatellite instability (MSI-H) rectal cancer	19/06/2023	11/07/2023	03/08/2023	Supported		
Mepolizumab	Treatment of chronic eosinophilic pneumonia	25/11/2019	23/12/2019	N/A	Not supported	19/06/2023	Not supported
Arsenic trioxide	Acute promyelocytic leukaemia - 1st line therapy in patients unsuitable for anthracycline-based therapy	26/09/2016	24/10/2016	N/A	Supported – partially superseded by NICE FAD 04/05/2018	10/07/2023	
Azacitidine	Relapsed angio-immunoblastic T cell lymphoma (second and third line) - for patients that are not fit/suitable for intensification of therapy with a BEAM conditioned autograft	18/05/2020	29/06/2020	N/A	Supported	10/07/2023	

**One Wales work programme
August 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Rituximab	Treatment of pemphigus and pemphigoid disease in adults and children where third- or fourth-line treatments, including steroids and steroid sparing treatments have failed.	26/06/2017	20/07/2017	N/A	Supported Indication changed to 2nd and 4th line treatment following 2018 review. Pemphigus vulgaris superseded by AWMSG advice 14/09/2022	10/07/2023	
Sorafenib	Maintenance treatment following allogeneic stem cell transplantation for acute myeloid leukaemia associated with a FLT3 ITD mutation	28/02/2022	31/03/2022	N/A	Supported	22/05/2023	Interim decision to continue for 3 years
Rituximab	Treatment of myasthenia gravis in adults 1st line and for refractory disease 4 th line and later. (reassessment in March 2023 to consider change in pathway to first line and later use)	20/03/2023	19/04/2023	25/04/2023	Supported		

**One Wales work programme
August 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Infliximab	Treatment of pulmonary sarcoidosis refractory to standard treatments and when there are no pharmacological alternatives	19/12/2022	03/03/2023	N/A	Supported		
Ustekinumab	Treatment of inflammatory bowel disease in children: ulcerative colitis following loss of response or non-response to anti-TNF and vedolizumab; Crohn's disease following loss of response or non-response to anti-TNF.	19/12/2022	03/03/2023	N/A	Supported		
Vedolizumab	Treatment of inflammatory bowel disease in children: ulcerative colitis following loss of response or non-response to anti-TNF treatment; Crohn's disease following loss of response or non-response to anti-TNF and ustekinumab.	19/12/2022	03/03/2023	N/A	Supported		
Infliximab	Treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids	28/11/2022	2/02/2023	N/A	Supported		

**One Wales work programme
August 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Vedolizumab	Treatment of Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab	28/11/2022	2/02/2023	N/A	Supported		
Bevacizumab	At a dose of 7.5 mg/kg in combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	24/06/2019 (re-assessment)	18/07/2019	N/A	Supported	24/10/2022	Interim decision to continue for 12 months
Rituximab + bendamustine	Treatment of indolent lymphomas, first line and relapsed. To include follicular lymphoma, Waldenstrom's and marginal zone lymphoma	27/03/2017	28/04/2017	N/A	Supported	24/10/2022	Interim decision to continue for 12 months
Rituximab + bendamustine	Treatment of mantle cell lymphoma, first line and relapsed	27/03/2017	28/04/2017	N/A	Supported	24/10/2022	Interim decision to continue for 12 months

**One Wales work programme
August 2023 continued**

Medicine	Indication	One Wales Medicines Assessment Group Date	Chief Executives/ AWMSG endorsement date	WG ratification date*	One Wales Interim Decision	Latest review meeting date	Review decision
Rituximab	Treatment of progressive fibrotic interstitial lung disease (not idiopathic pulmonary fibrosis) related to underlying connective tissue disease or idiopathic fibrotic non-specific interstitial pneumonia which has not responded to first line immunosuppressive therapy with either azathioprine or mycophenolate mofetil	29/04/2019	22/08/2019	N/A	Supported	29/11/2021	Interim decision to continue for 2 years